EZZ Life Science Holdings Ltd (ASX: EZZ) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

EZZ Life Science Holdings Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $137.27 million
P/E Ratio 18.00
Dividend Yield 1.20%
Shares Outstanding 47.17 million
Earnings per share 0.162
Dividend per share 0.04
Year To Date Return 353.08%
Earnings Yield 5.56%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • EZZ Life Science Holdings Ltd (ASX: EZZ)
    Latest News

    A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
    Healthcare Shares

    Up 630% this year AND profitable! This small ASX healthcare share is glowing

    Why has this stock delivered incredible returns this year? Let's find out.

    Read more »

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    05 Nov 2024 $0.0200 100.00% Final 09 Dec 2024
    16 May 2024 $0.0150 100.00% Interim 17 Jun 2024
    30 Oct 2023 $0.0100 100.00% Final 08 Dec 2023
    22 May 2023 $0.0098 100.00% Interim 23 Jun 2023
    03 Nov 2022 $0.0045 100.00% Final 16 Dec 2022
    09 Nov 2021 $0.0045 100.00% Final 16 Dec 2021

    EZZ ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About EZZ Life Science Holdings Ltd

    EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity,human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.

    EZZ Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Dec 2024 $2.91 $-0.01 -0.34% 38,235 $2.92 $3.02 $2.85
    19 Dec 2024 $2.92 $-0.02 -0.68% 56,191 $2.94 $2.97 $2.78
    18 Dec 2024 $2.94 $-0.14 -4.55% 104,674 $3.11 $3.28 $2.91
    17 Dec 2024 $3.08 $0.45 17.11% 172,352 $2.65 $3.10 $2.65
    16 Dec 2024 $2.63 $-0.01 -0.38% 22,664 $2.65 $2.65 $2.56
    13 Dec 2024 $2.64 $-0.01 -0.38% 19,216 $2.67 $2.69 $2.54
    12 Dec 2024 $2.65 $0.09 3.52% 47,243 $2.61 $2.68 $2.61
    11 Dec 2024 $2.56 $-0.02 -0.78% 42,070 $2.65 $2.67 $2.45
    10 Dec 2024 $2.58 $-0.09 -3.37% 108,928 $2.76 $2.76 $2.54
    09 Dec 2024 $2.67 $0.03 1.14% 157,557 $2.77 $2.88 $2.57
    06 Dec 2024 $2.64 $0.00 0.00% 95,561 $2.64 $2.76 $2.58
    05 Dec 2024 $2.64 $0.05 1.93% 48,177 $2.57 $2.64 $2.46
    04 Dec 2024 $2.59 $0.22 9.28% 138,577 $2.43 $2.62 $2.42
    03 Dec 2024 $2.37 $-0.04 -1.66% 41,947 $2.41 $2.46 $2.37
    02 Dec 2024 $2.41 $-0.12 -4.74% 100,353 $2.54 $2.58 $2.35
    29 Nov 2024 $2.53 $-0.16 -5.95% 20,207 $2.64 $2.64 $2.53
    28 Nov 2024 $2.69 $0.19 7.60% 99,256 $2.54 $2.69 $2.54
    27 Nov 2024 $2.50 $-0.04 -1.57% 25,718 $2.58 $2.59 $2.50
    26 Nov 2024 $2.54 $-0.11 -4.15% 119,281 $2.63 $2.74 $2.48
    25 Nov 2024 $2.65 $0.04 1.53% 145,368 $2.62 $2.70 $2.46
    22 Nov 2024 $2.61 $-0.24 -8.42% 173,681 $2.80 $2.86 $2.61

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    11 Dec 2024 Mark (Qizhou) Qin Buy 90,830 $246,149
    On-market trade.
    10 Dec 2024 Mark (Qizhou) Qin Issued 1,000,000 $2,550,000
    Issue of securities.
    10 Dec 2024 Mark (Qizhou) Qin Issued 30,000 $5,400
    Issue of securities. 30,000 Performance Rights
    06 Dec 2024 Lily (Hao) Huang Issued 5,000 $13,350
    Conversion of securities. Non-cash - estimated value
    06 Dec 2024 Ivan Oshry Issued 5,000 $13,350
    Conversion of securities. Non-cash - estimated value
    06 Dec 2024 Ivan Oshry Exercise 5,000 $13,350
    Conversion of securities. 10,000 Performance Rights, Non-cash -estimated value
    06 Dec 2024 Lily (Hao) Huang Exercise 5,000 $13,350
    Conversion of securities. Non-cash - estimated value, 10,000 Performance Rights
    06 Dec 2024 Glenn Cross Exercise 5,000 $13,350
    Conversion of securities. 10,000 Performance Rights, Non-cash -estimated value
    06 Dec 2024 Glenn Cross Issued 5,000 $13,350
    Conversion of securities. Non-cash - estimated value
    21 Aug 2024 Glenn Cross Issued 15,000 $1,200
    Issued under employee share plan.
    21 Aug 2024 Ivan Oshry Issued 15,000 $1,200
    Issued under employee share plan.
    21 Aug 2024 Lily (Hao) Huang Issued 15,000 $1,200
    Issued under employee share plan.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Ivan Oshry Non-Executive Director Oct 2020
    Mr. Oshry has more than 30 years of experience of legal practice in Australia and internationally, specializing in commercial and corporate law. Mr. Oshry was formerly a senior partner at Fluxmans Attorneys in Johannesburg and headed up the corporate department at Kemp Strang (which merged with Thomson Geer) in Sydney. He is Chair of the Risk Committee and a Member of the Human Resource Committee.
    Ms Lily (Hao) Huang Non-Executive Director Oct 2020
    Ms. Huang has over 20 years of experience in the wealth management and banking industry. She has been working with Citi Group Australia since 2017 as Vice President of the APAC Desk of the Investment Partnerships Division. He is Member of the Risk Committee and Chair of the Human Resource Committee.
    Mr Mark (Qizhou) Qin Chief Operating OfficerExecutive DirectorInterim Chief Executive Officer Sep 2018
    Mr. Qin is a co-founder of the Company with a track record of success in the skin care and health supplements industries. He has a background in management consulting and experience in sales and marketing. Mr. Qin also authored five books in sales and marketing for the consumer health industry between 2003 and 2008.
    Mr Glenn Walter Cross Non-Executive ChairmanNon-Executive Director Dec 2021
    Mr. Cross has 40 years of experience in life science sector domestically and internationally, including over 20 years in senior executive capacity. He was formerly CEO and COO of AusBiotech over 13 years. He is a Member of the Risk Committee and a Member of the Human Resource Committee.
    Ms Natalie Sylvia Climo Company Secretary
    -
    Anthony Guarna Chief Financial Officer
    -
    Natalie Sylvia Climo Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Macquarie Holdings Pty Ltd 17,016,000 38.31%
    Jnj Mok Pty Ltd 11,344,000 25.54%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 2,124,363 4.78%
    Yong Cao 1,760,000 3.96%
    New Continent Australia Pty Ltd 854,100 1.09%
    Zhaoying Wang 486,000 1.09%
    Haitao Zheng 470,000 1.06%
    Mars Family Investment Pty Ltd Mars Family A/C) 405,000 0.91%
    Citicorp Nominees Pty Ltd 400,614 0.90%
    Jing Chen 331,980 0.75%
    Oren Danziger 256,606 0.58%
    Finclear Services Pty Ltd Superhero Securities A/C) 156,009 0.35%
    Warbont Nominees Pty Ltd Unpaid Entrepot A/C) 152,850 0.34%
    Xiaojing Wang 150,000 0.34%
    George Khouri 130,000 0.29%
    J P Morgan Nominees Australia Pty Ltd 128,286 0.29%
    BNP Paribas Noms Pty Ltd 120,000 0.27%
    Comsec Nominees Pty Ltd 117,797 0.27%
    Emma Michelle Sievwright 115,688 0.26%
    Stephen Anthony Mander 113,040 0.26%

    Profile

    since

    Note